top of page
  • Writer's pictureagbiopro

After Kymera's raise, Nurix nabs $120M as it too hones in on clinical work

Sanofi- and Gilead Sciences-backed Nurix Therapeutics is following suit with rival biotech Kymera in raising a major cash haul for its protein modulation R&D work.

5 views0 comments


bottom of page